n-(3-chloro-7-indolyl)-1,4-benzenedisulphonamide and Vomiting

n-(3-chloro-7-indolyl)-1,4-benzenedisulphonamide has been researched along with Vomiting in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Droz, JP; Faber, MN; Ravic, M; Roché, H; Schellens, JH; Terret, C; Wanders, J; Zanetta, S	1

Trials

1 trial(s) available for n-(3-chloro-7-indolyl)-1,4-benzenedisulphonamide and Vomiting

Article	Year
Phase I clinical and pharmacokinetic study of E7070, a novel sulfonamide given as a 5-day continuous infusion repeated every 3 weeks in patients with solid tumours. A study by the EORTC Early Clinical Study Group (ECSG). European journal of cancer (Oxford, England : 1990), 2003, Volume: 39, Issue:8 Topics: Adult; Antineoplastic Agents; Area Under Curve; Dose-Response Relationship, Drug; Fatigue; Female; Hematologic Diseases; Humans; Hypokalemia; Infusions, Intravenous; Kidney Diseases; Male; Maximum Tolerated Dose; Middle Aged; Nausea; Neoplasms; Platelet Count; Sulfonamides; Vomiting	2003

Article

Year

Phase I clinical and pharmacokinetic study of E7070, a novel sulfonamide given as a 5-day continuous infusion repeated every 3 weeks in patients with solid tumours. A study by the EORTC Early Clinical Study Group (ECSG).

European journal of cancer (Oxford, England : 1990), 2003, Volume: 39, Issue:8

Topics: Adult; Antineoplastic Agents; Area Under Curve; Dose-Response Relationship, Drug; Fatigue; Female; Hematologic Diseases; Humans; Hypokalemia; Infusions, Intravenous; Kidney Diseases; Male; Maximum Tolerated Dose; Middle Aged; Nausea; Neoplasms; Platelet Count; Sulfonamides; Vomiting

2003